Phase 3 combination trials in advanced RCC
Checkmate214 - NCT02231749: Combination
PD-1
+ CTLA-4 inhibition
IMmotion151 - NCT02420821: Combination
PD-L1
+ VEGF
i hibiti
Javelin Renal 101 - NCT02684006: Combination
PD-L1 + VEGFR TK inhibition
Phase III N
=1070
Co-Primary endpoint
: PFS, OS
RANDOMISATION
Phase III N
=830
Co-Primary endpoint
: PFS, OS
n on
RANDOMISATION
Phase III N
=583
Primary endpoint
: PFS
RANDOMISATION
Nivolumab
+
Ipilimumab
Sunitinib
MPDL3280A
+
Bevacizumab
Sunitinib
Avelumab
+
Axitinib
Sunitinib
Keynote426 - NCT02853331: Combination
PD-1 +
VEGFR TK inhibition
CLEAR - NCT02811861:
Combination
VEGFR TK + mTOR/PD-L1
inhibition
Phase III N
=840
Co-Primary endpoint
: PFS, OS
RANDOMISATION
Phase III N
=735
Primary endpoint
: PFS
RANDOMISATION
Pembrolizumab +
Axitinib
Sunitinib
Lenvatinib
+
Everolimus
Sunitinib
Lenvatinib
+
Pembro
